Examining the Origin of Posttransplant Lymphoproliferative Disorder in a Patient After a Second Allogeneic Hematopoeitic Stem Cell Transplantation for Relapsed BCR-ABL Positive Acute Lymphoblastic Leukemia

BackgroundPosttransplant lymphoproliferative disease (PTLD) is a serious complication because of the reactivation of the Epstein-Barr virus (EBV). Although after solid organ transplantation (SOT) EBV is typically of recipient origin, after hematopoietic stem cell transplantation (HSCT) donor-derived